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Summary 
Several tumor antigens are recognized by autologous 
cytolytic T lymphocytes (CTL) on human melanoma 
MZ2-MEL. Some of them are encoded by genes MAGE.1 
and MAGE.3, which are not expressed in normal tis- 
sues except in testis. Here, we report the identification 
of a new gene that codes for another of these antigens. 
This gene, named BAGE, codes for a putative protein 
of 43 aa and seems to belong to a family of several 
genes. The antigen recognized by the autologous CTL 
consists of BAGE-encoded peptide AARAVFLAL 
bound to an HLA-Cw*1601 molecule. Gene BAGE is 
expressed in 22% of melanomas, 30% of infiltrating 
bladder carcinomas, 1'0% of mammary carcinomas, 
8% of head and neck squamous cell carcinomas, and 
6% of non-small cell lung carcinomas. Like the MAGE 
genes, it is silent in normal tissues with the exception 
of testis. Because of its tumor-specific expression, the 
BAGE-encoded antigen may prove useful for cancer 
immunotherapy. 
Introduction 
Cytolytic T lymphocytes (CTL) directed against human tu- 
rnor cells can often be obtained by culture of irradiated 
tumor cells with autologous iymphocytes (reviewed by 
Boon et al., 1994). From such a responder T cell population 
obtained against melanoma cell line MZ2-MEL, it was pos- 
sible to derive a large number of stable anti-tumor CTL 
clones, which showed specificity for the tumor cells inso- 
far as they did not lyse natural killer target cells, such as 
K562, autologous fibroblasts, and autologous Epstein- 
Barr virus (EBV)-transformed lymphobtastoid cells (Herin 
et al., 1987). These CTL clones were used to select resis- 
tant variants of MZ2-MEL and the analysis of these anti- 
gen-loss variants led to the conclusion that several distinct 
antigens were recognized on MZ2-MEL by autologous 
CTL (Van den Eynde et al., 1989). 
A gene transfection approach led to the identification of 
the gene coding for one of these antigens, namely MZ2-E. 
This gene, named MAGE-1, is not expressed in normal 
tissues except testis and it is expressed in approximately 
'37% of melanoma tumor samples (van der Bruggen et al., 
1991; De Smet et al., 1994). Antigen MZ2-E consists of 
a MAGE-l-encoded nonapeptide presented by an HLA-A1 
molecule (Traversari et al., 1992a). Another antigen recog- 
nized by CTL on melanoma MZ2-MEL is also encoded by 
MAGE-1 and it is presented by an HLA-Cw* 1601 molecule 
(van der Bruggen et al., 1994b). Gene MAGE-1 belongs 
to a family of at least 12 closely related genes, and another 
member of this gene family, namely MAGE-3, codes for 
a third antigen present on MZ2-M EL. Like MZ2-E, this anti- 
gen is presented by HLA-A1 (De Plaen et al., 1994; Gaugler 
et al., 1994). 
We report here the identification of a new gene, which 
codes for yet another antigen recognized on MZ2-MEL by 
autologous CTL. This gene is not related to the MAGE 
family. 
Results 
CTL 82•82 Recognizes an Antigen Presented 
by HLA-Cw* 1601 
Melanoma cell line MZ2-MEL was derived from an abdomi- 
nal metastasis of patient MZ2 and clonal line MZ2-MEL.3.0 
was obtained by limiting dilution. After more than 150 gen- 
erations in culture, this subline was found to be resistant 
to a large fraction of autologo us CTL clones that had strong 
lytic activity on MZ2-MEL.3.0. This resistant subline was 
named MZ2-MEL.3.1 (Figure 1A; Van den Eynde et al., 
1989). The target antigen of the CTL that failed to lyse 
MZ2-MEL.3.1 was named MZ2-B, under the erroneous 
assumption that a single antigen had been lost by this 
subline. Subsequent analysis indicated that subline MZ2- 
MEL.3.1 had lost the genes coding for HLA-A29, B44, and 
Cw'1601 (van der Bruggen et al., 1994b). Transfection 
experiments with HLA-Cw* 1601 indicated that several of 
the anti-B CTL recognized an antigen presented by the 
product of this HLA-C allele (Figure 1A). Some of these 
CTL recognized an antigen, named Bb, that turned out to 
be encoded by MAGE-1 (van der Bruggen et al., 1994b). 
Others appeared to recognize another antigen, because 
they failed to recognize COS-7 cells transfected with HLA- 
Cw'1601 and MAGE-?. CTL 82•82 belonged to this group 
and its target antigen was named Ba. In addition to MZ2- 
MEL, CTL 82•82 also recognized two other melanoma cell 
lines carrying the HLA-Cw* 1601 allele. These two mela- 
noma cell lines stimulated tumor necrosis factor (TNF) 
release by CTL 82•82 (van der Bruggen et al., 1994b) and 
were lysed by it, albeit to a lesser extent han the MZ2-MEL 
cells (Figure 1B). 
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Figure 1. Lytic Activity of CTL Clone 82/82 on MZ2-MELSublinesand 
Other Melanoma Lines 
Chromium release was measured after 4 hr. 
(A) Subline MZ2-MEL.3.1 was obtained by extending the culture of sub- 
clone MZ2-MEL.3.0 for more than 150 generations. MZ2-MEL.B.TC.4 
was obtained by transfecting the HLA-Cw*1601 gene into a subline 
derived from MZ2-MEL.3.1. 
(B) Clonal ine MZ2-MEL.43 was derived from MZ2-MEL.3.0 and mela- 
noma lines MI4024/1-MEL and LB17-MEL were derived from HLA- 
Cw* 1601 patients. 
Isolation of a cDNA Coding for Antigen MZ2-Ba 
We set out to identify the gene coding for the antigen 
recognized by CTL 82•82. Our approach involved the co- 
transfection of the HLA-Cw*1601 cDNA with a cDNA li- 
brary derived from clonal subline MZ2-MEL.43, which was 
also lysed by CTL 82182 (Figure 1B). The cDNAs were 
cloned in expression vector pcD-SR~, which contains the 
replication origin of SV40, and they were transfected into 
COS-7 cells. This vector provides considerable pisomal 
multiplication in the transfected cells and, therefore, high 
expression of the antigen (Seed and Aruffo 1987; Brichard 
et al., 1993; Coulie et al., 1994). 
The library, which contained approximately 66,000 in- 
serts, was divided into pools of either 400 or 200 bacteria. 
Each cDNA pool was cotransfected with the HLA-Cw* 1601 
construct into duplicate microcultures of COS-7 cells. CTL 
82•82 was added 2 days later to each transfected microcul- 
ture. After 24 hr, the concentration of TNF in the superna- 
tant was estimated bymeasuring its cytotoxic effect on 
cells of WEHI-164 clone 13. Among the 384 pools of 
cDNAs (297 of 200 bacteria and 87 of 400) that were 
transfected, two produced positive supernatants con- 
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Figure 2. Stimulation of CTL 82•82 by COS-7 Cells Transfected with 
cDNA-AD5 and with an HLA-Cw*1601 cDNA, or with Each of These 
cDNAs Alone 
The cDNAs were inserted in expression vector pcD-SRm CTL 82•82 
was added 1 day after the transfection and the TNF content of the 
supernatant was estimated 1day later by testing its toxicity on cells 
of WEHI-164 clone 13. Positive and negative controls were made with 
MZ2-MEL.43 and MZ2-MEL.2.2.5 cells. 
taining more than 40 pg/ml of TNF, whereas TNF concen- 
tration in all the microcultures transfected with the other 
pools was lower than 5 pg/ml. From one of these cDNA 
pools, which contained 400 independent bacteria, we sub- 
cloned 800 bacteria. Plasmid DNA was extracted from 
each of them and transfected into COS-7 cells together 
with the HLA-Cw*1601 construct. Twelve clones con- 
ferred recognition by CTL 82182. The result obtained with 
one of them, namely cDNA-AD5, is represented in Fig- 
ure 2. 
To confirm the result obtained with cDNA-AD5 in tran- 
sient transfections, stable transfectants were also pre- 
pared. P1.HTR, a highlytransfectable variant derived from 
mouse tumor cell line P815 (Van Pel et al., 1985), was 
transfected with both HLA-Cw*1601 and cDNA-AD5. 
Transfected cells were lysed by CTL 82•82, indicating that 
the antigen can also be processed in these mouse cells 
(Figure 3A). 
Sequence of Gene BAGE 
Even though the sequence of cDNA-AD5 is 1004 bp long, 
the largest open reading frame comprises only 132 bp and 
encodes a protein of 43 aa (Figure 4). The sequence bears 
no significant similarity to any other sequence presently 
recorded in data banks, except for an Alu repeat sequence 
(nucleotides 385-484) located outside the coding part. 
We propose to name BAGE the gene that corresponds 
to cDNA-AD5. 
We prepared a Southern blot with DNA extracted from 
blood lymphocytes of patient MZ2 and from the melanoma 
line MZ2-MEL.3.0. This blot was hybridized with a 121 bp 
probe including almost all the BAGE coding sequence. 
We observed four bands in lanes containing DNA digested 
with EcoRI and six bands after Hindlll digestion (Figure 
5). Considering thesmall size of the probe and considering 
the absence of EcoRI and Hindlll restriction sites in the 
coding sequence, these results indicate that BAGE be- 
longs to a family of several related genes. 
Expression of Gene BAGE 
A Northern blot prepared with poly(A) + RNA of subline 
MZ2-MEL.43 was hybridized with a BAGE probe covering 
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Figure 3. Lysis of Mouse Cells Expressing HLA-Cw*1601 and Trans- 
fected with BAGE or Incubated with the BAGE-Encoded Peptide 
(A) Lysis by CTL clone 82/82 of PI.HTR mouse cells cotransfected 
with expression vectors carrying H LA-Cw*1601 and cDNA-AD5. Un- 
transfected P 1.HTR and P 1. HTR transfected with H LA-Cw * 1601 alone 
were also tested. 
(B) Lysis by CTL clone 82/82 of P 1. HTR transfected with H LA-Cw * 1601 
and incubated with 1 I~M of the BAGE-encoded nonapeptide. Lysis of 
chromium-labeled cells was tested after 4 hr.
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nucleotides 100-385. Two bands of approximately 1 and 
2.4 kb were observed (Figure 6). The expression of BAGE 
was also studied by reverse transcription and polymerase 
chain reaction (PCR) amplification, with primers located 
on both sides of the coding part of the gene (see Figure 
4). These primers are located in two different exons: the 
PCR amplified a fragment of 1.7 kb on DNA of MZ2- 
MEL.43 and a fragment of 286 bp on cDNA (Figure 7). 
No expression of gene BAGE was found in normal adult 
tissues except in testis (Figure 7; Table 1). The gene was 
also silent in placenta and umbilical cord and in several 
tissue samples fro~ fetuses older than 20 weeks. We 
found no expression of BAGE in the twelve EBV-trans- 
formed lymphoblastoid cell lines and in blood lymphocytes 
stimulated with phytohemagglutinin. 
Of tumors of various histological origins, 600 samples 
were analyzed for expression of BAGE (Table 2; Figure 
7). The gene is expressed mainly in melanomas (22%), 
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TGCTCCAAGC CAGGCTGATG AAGGAGGAGT CCCCTGTGGT GAGCTGGAGG TTGGAGCCTG 300 
E D G T A L C F I F  43 
AAGACGGCAC AGCTCTGTGC TTCATCTTCT GAGGTTGTGG CAGCCACGGT GATGGAGACG 360 
GCAGCT~AAC AGGAGCAATA GGAGGAGATG AGTTTCACT GTGTCAGCCA GGATGGTCTC 420 
GATCTCCTGA CCTCGTGATC CGCCCGCCTT GGCCTTCCAA AGTGCCGAGA TTACAGCGAT 480 
GTGCATTTTG TAAGCACTTT GGAGCCACTA TC~AATGCTG TGAAGAGAAA TGTACCCAGA 540 
TGTATCATTA TCCTTGTGCT GCAGGAGCCG GCTCCTTTCA GGATTTCAGT CACATCTTCC 600 
TGCTTTGTCC AGAACACATT GACCAAGCTC CTGAAAGATG TAAGTTTACT ACGCATAGAC 660 
TTTT~AACTT CAACCAATGT ATTTACTGAA AATAACAAAT GTTGTA~TT CCCTGAGTGT 720 
TATTCTACTT GTATTAAAAG GTAATAATAC ATAATCATTA AAATCTGAGG GATCATTGCC 780 
AGAGATTGTT GGGGAGGGAA ATGTTATCAA CGGTTTCATT GAAATTAAAT CCA~GTT 840 
ATTTCCTCAG AAAAATCAAA TAAAGTTTGC ATGTTTTTTA TTCTTAAAAC ATTTTAAAAA 900 
CCACTGTAGA ATGATGTAAA TAGGGACTGT GCAGTATTTC TGACATATAC TATAAAATTA 960 
TTAAAAAGTC AATCAGTATT CA~CATCTTT TACACTAA~A AGCC 1004 
Figure 4. Sequence of BAGE cDNA-AD5 and of the Putative Protein 
of 43 aa Encoded by the Largest Open Reading Frame 
The sequence corresponding to the peptide recognized i  association 
with HLA-Cw*1601 by MZ2-CTL 82/82 is indicated in a box. The se- 
quence of primers VDB85 (sense) and VDB86 (antisense) used for 
PCR amplification are underlined with arrows. The sequence of cDNA-A5 
is available from EMBL/GenBank/DDBJ under accession number 
U19180. 
Figure 5. Southern Blot of DNA Extracted from Melanoma Cell Line 
MZ2-MEL3.0, Blood Lymphocytes from Patient MZ2, and Mouse Cell 
Line P1 .HTR 
The DNA was digested with EcoRI or Hindlll. The membrane was 
hybridized with a probe including almost all the BAGE coding sequence 
(nucleotides 211-331) and it was washed under stringent conditions. 
bladder carcinomas (15%), mammary carcinomas (10%), 
and head and neck squamous cell carcinomas (8%). A 
smaller proportion of positive samples was found in sarco- 
mas (6%) and in non-small cell lung carcinomas (6%). No 
expression of BAGE was found in renal, cotorectal, and 
prostatic carcinomas, leukemias, or lymphomas. With 
very few exceptions, tumor samples that expressed BAGE 
also expressed one of the MAGE genes (data not shown). 
BAGE was more frequently expressed in metastatic le- 
sions of melanomas (26%) than in primary lesions (8%). 
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Figure 6. Northern Blot Analysis of the Expression of Gene BAGE in 
MZ2-MEL.43 Cells 
Lanes contained 5l~g of poly(A) + RNA. The membrane was hybridized 
with a probe including the BAGE coding sequence (nucleotides 100- 
385) and washed under stringent conditions. Control hybridization was 
performed on the same membrane with a [5-actin probe. 
in transitional cell carcinomas of the urinary bladder, 30% 
of invasive tumors (stages T2-T4 (Mostofi et al., 1973)) 
expressed BAGE, while no expression was observed in 
superficial tumors (stages Ta-T1). BAGE was expressed 
in a higher proportion of tumor cell lines than of tumor 
samples: 32 of 60 melanoma (53%) and 3 of 15 colorectal 
carcinoma (20%) cell lines were positive. This has also 
been observed with MAGE genes. It may be owing to the 
fact that tumor cell lines are more readily derived from 
metastatic tumors. 
Identification of the Antigenic Peptide 
To identify the region of the BAGE sequence that codes 
for the antigenic peptide presented by HLA-Cw* 1601, we 
produced a large number of truncated BAGEcDNA clones. 
By digesting BAGE cDNA-AD5 with exonuclease III for 
various incubation times, we generated progressive de- 
letions starting from the 3' end. The truncated cDNAs 
were transfected into COS-7 cells, together with the HLA- 
Table 1. Expression of Gene BAGE by Normal Adult and Fetal 
Tissues 
Adult tissues Expression* 
Adrenal gland 
Bone marrow 
Brain 
Breast 
Cerebellum 
Colon 
Heart 
Kidney 
Liver 
Lung 
Melanocytes 
Muscle 
Ovary 
Prostate 
Skin 
Sperm 
Splenocytes 
Stomach 
Testis + 
Thymocytes 
Urinary bladder 
Uterus 
Placenta 
Umbilical cord 
Benign naevus 
Fetal tissues1" Expression 
Fibroblasts 
Brain 
Liver 
Spleen 
Thymus 
Testis 
* Expression of gene BAGE was tested by RT-PCR amplification of
total RNA, with the primers shown on Figure 4. Absence of PCR prod- 
uct is indicated by (minus) and presence by (plus). 
1" Fetal tissues derived from fetuses older than 20 weeks. 
Cw'1601 cDNA, to test for their ability to code for the 
antigen. Sequence comparison of the longest negative 
(nucleotides 1-206) and the shortest positive cDNA (nucle- 
otides 1-267) indicated that the antigenic peptide was en- 
coded by the first 67 nt of the open reading frame. 
Several synthetic peptides were prepared on this basis. 
Sensitization of a lymphoblastoid cell line from patient MZ2 
to lysis by CTL 82/82 was observed with nonapeptide AAR- 
AVFLAL (amino acids 2-10; see Figure 4). Half-maximal 
lysis was obtained at a peptide concentration of 30 nM 
(Figure 8). Nonapeptides that did not include the N-terminal 
Ala or the C-terminal Leu were not able to sensitize target 
cells to lysis. When P1.HTR cells transfected with HLA- 
Cw* 1601 were incubated with nonapeptide AARAVFLAL, 
they were also lysed by CTL 82/82 (see Figure 3B). 
From two MLTC set up with different blood samples of 
patient MZ2, we derived six CTL c/ones that recognized 
the BAGE/HLA-Cw* 1601 antigen on MZ2-MEL cells. They 
also produced TNF in the presence of COS-7 cells that 
had been either cotransfected with HLA-Cw*1601 and 
BAGEcDNA-AD5, or that had been transfected with HLA- 
Cw* 1601 and incubated with nonapeptide AARAVFLAL 
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Figure 7. PCR Amplification of cDNAs from 
Melanoma Lines, Tumor and Normal Tissue 
Samples, and of Genomic DNA from Subline 
MZ2-MEL.43 
The cDNA was obtained with an oligo(dT) 
primer. PCR amplification was performed on 
100 ng of cDNA with BAGE-specific primers 
VDB85 (sense) and VDB8S (antisense). Hu- 
man ~-actin amplification was also performed 
on the cDNA samples to check the quality of 
RNA preparations. PCR products were visual- 
ized on a 1.5% agarose gel stained with ethid- 
ium bromide. 
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Table 2. Expression of Gene BAGE by Tumor Samples 
Number of BAGE 
Histological type positive tumors* 
Melanomas 40/178 
primary lesions 3/38 
metastatic lesions 37/140 
Bladder carcinomas 9/62 
superficial tumor~ 0/32 
infiltrating tumors 9/30 
Mammary carcinomas 8•79 
Head and neck squamous cell carcinomas 4/53 
Lung carcinomas NSCLCt 4/64 
Sarcomas 1/18 
Renal carcinomas 0/50 
Colorectal carcinomas 0/42 
Prostatic carcinomas 0/22 
Leukemias and lymphomas 0/22 
* Expression of gene BAGE was tested by RT-PCR amplification of 
total RNA with the primers shown on Figure 4. 
t NSCLC, non-small cell lung carcinomas. 
(data not shown). CTL clone 82/1 expressed V~2 and V~3 
and V[~13. CTL clone 25/244 expressed Va8 and VI38, and 
CTL clone 82/82 expressed V~3 and Ve4 and V~13. It 
appears, therefore, that at least three different CTL precur- 
sors from the same patient can recognize the same BAGE 
antigenic peptide. This was previously observed for the 
MAGE antigens presented by HLA-Cw* 1601 (van der Brug- 
gen et al., 1994b) and HLA-A1 (P. Romero and P. C., un- 
published data). Several reports have described the oc- 
curence of mature ~ T cells that have undergone two 
productive Ve rearrangements and have, therefore, the 
potential to express two V~ genes and two T cell receptors 
(reviewed by Padovan et al., 1993). 
Discussion 
So far, two main classes of antigens recognized by autolo- 
gous CTL have been found on human melanoma. The 
antigens of the first class are encoded by genes that are 
expressed very specifically in tumors. An antigen encoded 
by gene MAGE-1 was the first example (van der Bruggen 
et al., 1991), followed by other antigens encoded by genes 
MAGE-1 and MAGE-3 (Gaugler et al., 1994; van der Brug- 
gen et al., 1994a, 1994b). A tumor rejection antigen ob- 
served on mouse mastocytoma P815 also resulted from 
the activation of a gene that is silent in all normal adult 
tissues with the exception of testis (Van den Eynde et al., 
1991). The second class of antigens represents differenti- 
ation antigens encoded by genes that are expressed only 
in melanocytes and melanomas. Antigens encoded by ty- 
rosinase were examples of this class (Brichard et al., 1993; 
Robbins et al., 1994; W61fel et al., 1994), which also com- 
prises antigens encoded by Melan-A/MART-1 (Coulie et 
al., 1994; Kawakami et al., 1994) and gp100/pmell 7 (Bak- 
ker et al., 1994; Cox et al., 1994). 
The antigen encoded by gene BAGE is a new member 
of the first class. We decided to use the suffix "AGE" in 
the names of the antigen-coding enes that are silent in 
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Figure 8. Lysis by CTL 82•82 of Lymphoblastoid Cell Line MZ2-EBV 
Incubated with BAGE-Encoded Peptide AARAVFLAL 
We incubated 1000 51Cr-labeled MZ2-EBV target cells in 96-well mi- 
croplates in the presence of various concentrations ofpeptide for 30 
min at 37°C. An equal volume containing 3000 CTL was then added. 
Chromium release was measured after 4 hr at 37°C. We have indicated 
the-final concentration ofpeptides during the incubation of the target 
cells with the CTL. The arrow indicates the percentage of lysis of 
MZ2-MEL.43 cells. 
normal adult tissues except testis. Because the expres- 
sion of BAGE was tested by reverse transcription (RT) and 
PCR, the absence of a detectable product in normal tis- 
sues indicates a level of expression lower than 0.1% of 
that observed in tumor MZ2-MEL. Our observations with 
cells expressing various amounts of the MAGE- 1 message 
suggest that this level should not allow for recognition by 
anti-BAGE CTL. The expression of the BAGE gene by tes- 
tis cells does not imply that these cells present the BAGEl 
HLA-Cw* 1601 antigen, because sperm cells and their pre- 
cursors do not express MHC molecules on their surface 
(Haas et al., 1988). 
Gene BAGE was found to be expressed in a significant 
proportion of tumor samples not only of melanomas but 
also of tumors of other histological origins. However, it is 
possible that some tumors samples that were positive in 
the RT-PCR test did not express BAGEbut another closely 
related gene. Like MAGE genes, BAGE appears to belong 
to a family of several genes that hybridize with the same 
probe. It is, therefore, difficult o exclude that the message 
of some of these related genes could be amplified with the 
RT-PCR primers that we used. However, this is probably 
rare, because we sequenced the cloned RT-PCR prod- 
ucts of five positive melanoma samples and two testis 
samples and all contained the exact BAGE sequence. An- 
other reason to be confident in the validity of our PCR 
assay is that the two melanoma lines that showed positive 
PCR for both BAGE and H LA-Cw* 1601 were lysed by the 
CTL that recognize the BAGE antigen. 
It is noteworthy that melanomas that express BAGE 
and do not express any of MAGE-1, MAGE-2, MAGE-3, 
or MAGE-4 are extremely rare: 45/178, i.e., 25% of the 
melanoma tumors tested were negative for MAGE-1-4, 
whereas only 1/40, i.e., 2.5% of BAGE-positive melanoma 
tumors were negative for MAGE-1-4. Also, the tumor types 
in which BAGE genes are not expressed are those in which 
MAGE genes are never or very rarely expressed. Another 
similarity between BAGE and MAGE is that both genes 
are more frequently expressed in metastatic melanomas 
than in primary melanomas and in invasive transitional 
cell bladder carcinomas than in superficial bladder carci- 
nomas (Patard et al., 1995). Possibly, BAGE and MAGE 
expression arises in the primary tumor, in some cells that 
then metastasize preferentially. Alternatively, MAGE- and 
BAGE-positive tumors may be more invasive. 
BAGE codes for a short protein of 43 aa. The function 
of this protein is unknown. The amphipathic haracter of a 
region of the BAGE protein (amino acids 16-30) resembles 
that of fusion-induction peptides of viral proteins. This sug- 
gests that the BAGE protein could induce local membrane 
destabilization, or that it could disrupt protein-protein or 
DNA-protein interactions (Horth et al., 1991; Von~che et 
al., 1992). 
The BAGE antigenic peptide is coded by the sequence 
located immediately behind the START codon. This N-termi- 
nal location was also observed for a tyrosinase peptide 
binding to HLA-A2 (WSIfel et al., 1994), HLA-Cw*1601, 
the presenting molecule of the BAGE antigen, cannot be 
identified in serological assays, but its expression can be 
tested by reverse transcription and nested PCR. Approxi- 
mately 7% (7 of 99) of Caucasian individuals were found 
to express this HLA allele (van der Bruggen et al., 1994b). 
The concentration of HLA-C molecules on the cell surface 
has been reported to be about 10-fold lower than that of 
HLA-A and HLA-B, possibly because of less efficient bind- 
ing to 132-microglobulin (Neefjes and PIoegh 1988). Never- 
theless, we find that both MAGE and BAGE code for a 
peptide recognized on a HLA-C molecule, suggesting that 
HLA-C molecules also play a significant role in the presen- 
tation of antigens to CTL. 
Because of the relatively small proportions of HLA- 
Cw* 1601 individuals (7%) and of melanomas that express 
BAGE (22%), only 2% of melanoma patients ought to ex- 
press the relevant antigen on their tumor cells. Other 
BAGE peptides may be found to bind to other HLA mole- 
cules, as is the case for MAGE-1 and MAGE-3, but the 
small size of the BAGE protein should limit the number 
of these peptides (van der Bruggen et al., 1994a, 1994b). 
Even though the proportion of patients eligible for BAGEl 
HLA-Cw*1601 immunization is small, we believe that im- 
munization of cancer patients against BAGE antigen 
should be undertaken, as this should allow immunization 
of some patients against both MAGE and BAGE antigens. 
Such combined immune attacks on tumors may be a con- 
dition for therapeutic success. 
Experimental Procedures 
Cell Lines 
Melanoma cell line MZ2-MEL was derived from an abdominal metasta- 
sis of patient MZ2 and a number of subclones were obtained, Subline 
MZ2-ME/.3,0 was obtained by limiting dilution, Subline MZ2-MEL.3,1 
was obtained by extending the culture of subclone MZ2-MEL.3,0 for 
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more than 150 generations. Subline MZ2-MEL.43 was derived by lim- 
iting dilution from MZ2-MEL.3.0 cells that had survived to a mutagen 
treatment (H~rin et al., 1987; Van den Eynde et al., 1989). Clonal 
subline MZ2-MEL.2.2, which does not express antigen MZ2-E, was 
selected from subclone MZ2-MEL.3.1 with an autologous anti-MZ2-E 
CTL clone (Van den Eynde et al., 1989). Subline MZ2-MEL.2.2.5 was 
selected from subline MZ2-MEL.2.2 with an anti-MZ2-F CTL clone. 
MZ2-MEL.B.TC.4 was obtained by transfecting the HLA-Cw*1601 
gene into subline MZ2-MEL.2.2.5 (van der Bruggen et al., 1994b). 
Melanoma cell lines were grown as previously described (Van den 
Eynde et al., 1989; Traversari et al., 1992b). Autologous CTL clone 
82182 was derived from peripheral blood lymphocytes (PBL) of patient 
MZ2 and grown in conditions similar to those previously described 
(Traversari et al., 1992b). Lymphoblastoid cell line MZ2-EBV was de- 
rived from patient MZ2 by standard techniques. Mouse cell line 
PI.HTR was derived from mastocytoma P815 (Van Pel et al., 1985). 
PI.HTR cells were cotransfected by the phosphate calcium precipitate 
method with plasmid pSVtkneol~ conferring resistance to geneticin 
(Nicolas and Berg, 1983) and HLA-Cw*1601 alone, or HLA-Cw*1601 
and BAGE cDNA-AD5, cDNAs were inserted in expression vector pcD- 
SR~ (received from K. Moore, DNAx, Palo Alto, California; Takebe et 
al., 1988). Cional sublines were isolated from a geneticin-resistant 
transfected population. 
Construction of the cDNA Library 
Poly(A) ÷ RNA was extracted from MZ2-MEL.43 cells using mRNA ex- 
traction kit Fastrack (Invitrogen Corporation, Oxon, United Kingdom). 
mRNA was converted to cDNA using random primers, Iigated to adap- 
tors as described in the SuperScript plasmid system kit (GIBCO BRL, 
Gaithersburg, Maryland), and inserted into the EcoRI site of expression 
vector pcD-SR*z. Recombinant plasmids were electroporated into 
Escherichia coil JM101 and selected with ampicillin (50 i~g/ml). The 
library contained 66,000 inserts and was divided into 87 pools of 400 
bacteria and 297 pools of 200 bacteria. Each of these pools comprised 
approximately 280 or 140 different cDNAs, respectively, as about 70% 
of the plasmids carried an insert. Each pool of bacteria was amplified 
to saturation and plasmid DNA was extracted by the alkaline lysis 
method. 
Transfection of COS-7 Cells 
Transfection experiments were performed by the DEAE-dextran-chlo- 
roquine method (Seed and Aruffo 1987; Brichard et al., 1993; Coulie 
et ai., 1994). In brief, 1.5 x 104 COS-7 cells were transfected with 
100 ng of plasmid pcD-SR(~ containing cDNA of HLA-Cw*1601, and 
100 ng of a poolOf the cDNA library or 100 ng of a cDNA clone. The 
HLA-Cw*1601 cDNA was isolated from a cDNA library prepared with 
RNA extracted from subline MZ2-MEL.43 (van der Bruggen et al., 
1994b). Transfected COS-7 cells were tested in a CTL stimulation 
assay after 24 or 48 hr. 
CTL Stimulation Assay 
Transfectants were tested for their ability to stimulate the production of 
TNF by CTL (Traversari et al., 1992b). In brief, in microwells containing 
target cells, 1500 CTL were added in 100 i~1 of Iscove medium (GIBCO 
BRL) containing 10% human serum and 20 U/ml r-hulL-2. After 24 
hr, the supernatant was collected and its TNF content was determined 
by testing its cytotoxic effect on cells of WEHI-164 clone 13 (Espevik 
and Nissen-Meyer, 1986) in a M'FT colorimetric assay (Hansen et al., 
1989; Traversad et al., 1992b). 
DNA Sequencing and Homology Search 
DNA sequencing analysis was performed by specific priming with syn- 
thetic oligonucleotides. The sequencing reactions were performed by 
the dideoxy-chain termination method (T7 Sequencing Kit, Pharmacia, 
Uppsala, Sweden, ATaq Cycle-Sequencing Kit, United States Bio- 
chemical, Cleveland, Ohio). The computer search for the sequence 
homology was done with programs FASTA@EMBL-Heidelberg and 
blast@ncbi.nlm.nih.gov. The sequence of BAGE cDNA-AD5 is avail- 
able from EMBL/GenBank/DDBJ under accession number U19180. 
Southern Blot Analysis 
DNA from melanoma cell line MZ2-MEL.3.0, PBL of patient MZ2, and 
mouse cell line P1.HTR were digested with EcoRI or Hindlll. DNA 
capillary transfer was done by alkaline blotting on a Zeta-Probe mem- 
brane (Bio-Rad). Following transfer, the membrane was rinsed in 2 x 
SSC, baked for 1 hr at 80°C and pretreated for 30 min at 60°C in 6 x 
SSC, 10x Denhardt's solution. The membrane was then hybridized 
for 18 hr at 65°C in 3.5x SSC, l x  Denhardt's solution, 25 mM 
NaH2PO4 (pH 7.0), 0.5% SDS, 2 mM EDTA, 100 p.g/ml of herring 
sperm DNA, and 2 x 106 cpm/ml of a 121 bp 32P-labeled probe (BAGE 
cDNA-AD5, nucleotides 211-331) produced by PCR. The membrane 
was then washed at 65°C two times for 15 min in 2x SSC, 0.5% 
SDS, then for 15 min in 0.2 x SSC, 0.1% SDS, and autoradiographed 
for 10 days. 
Northern Blot Analysis 
Poly(A) + RNA from MZ2-MEL.43 was prepared using mRNA extraction 
kit Fastrack (Invitrogen Corporation, Oxon, United Kingdom). Total 
RNA from mouse kidney tissue was extracted by the guanidine-iso- 
thiocyanate procedure as described (Davis et al., 1986). Poly(A)* RNA 
was purified from total RNA on an oligo(dT) column. For the Northern 
blot analysis, 5 p.g of poly(A) ÷ RNA from subline MZ2-MEL.43 and 5 
p.g of poly(A) + RNA from mouse kidney cells were fractionated on 1% 
agarose gel containing 0.66 M formaldehyde and transfered on a mem- 
brane (Hybond C-extra, Amersham) in 10 x SSC. The membrane was 
prehybridized for 15 rain at 60°C in 10% dextran sulfate, 1% SDS, 
and 1 M NaCI and hybridized overnight at 60°C in the same solution 
with 2 x 106 cpm/ml of a 286 bp 3~P-labeled probe (BAGE cDNA-AD5, 
nucleotides 100-385) produced by PCR and 100 i~g/ml of herring 
sperm DNA. The membrane was washed at room temperature in 0.2 x 
SSC for 10 min and then washed two times for 20 rain at 60°C in 
0.2 x SSC supplemented with 0.1% SDS, and autoradiographed for 
15 hr. Control hybridization was performed on the same membrane 
with a mouse I~-actin probe. 
PCR Assay for BAGE Expression 
Total RNA was extracted by the guanidine-isothiocyanate procedure 
as described (Davis et al., 1986). Reverse transcription was performed 
on 2 p.g of total RNA in a reaction volume of 20 p.I with 4 p,I of 5x 
reverse transcriptase buffer (GIBCO BRL), 2 pl of a 20 mM solution 
of oligo(dT)~s primer, 20 U of RNasin (Promega Biotec, Madison, Wis- 
consin), 2 I~1 of 0.1 M dithiotreitol, and 200 U of MoMLV reverse tran- 
scriptase (GIBCO BRL). The reaction was incubated at 42°C for 60 
rain. Of the cDNA product, one-twentieth was then supplemented with 
5 I~1 of 10 x thermostable DNA polymerase buffer (Finnzymes OY, 
Espoo, Finland), 1 I11 each of 10 mM solution of dNTP, 1 Id each of 
25 mM solution of primers, 1 U of DynaZyme (Finnzymes OY, Espoo, 
Finland), and water to a final volume of 50 p,l. The PCR primers were 
5'-TGGCTCGTCTCACTCTGG-3' (VDB85, sense, nucleotides 100- 
117) and 5'-CCTCCTATTGCTCCTGTTG-3' (VDB86, antisense, nucle- 
otides 367-385). The PCR was performed for 30 cycles (1 rain at 94°C, 
2 min at 62°C, and 2 min at 73°C). Of the PCR product, 10 pl was 
size fractionated on a 1,5% agarose gel. The quality of RNA prepara- 
tions was tested by PCR amplification of human ~-actin cDNA with 
primers 5'-GGCATCGTGATGGACTCCG-3' (exon 3, sense) and 5'- 
GTCGGAAGGTGGACAGCGA-3' (exon 6, antisense) for 21 cycles of 
1 min at 94°C, 2 rain at 68°C, and 2 min at 72°C by AmpliTaq DNA 
polymerase (Perkin-Elmer Cetus, Norwalk, Connecticut). 
Production of Progressive Deletions in BAGE cDNA-AD5 
BAGE cDNA-AD5 was inserted in the EcoRI site of pcDNAI/Amp (In- 
vitrogen Corporation, San Diego, California). The plasmid was opened 
with Notl and Sphl before being digested with exonuclease III. This 
treatment was performed with the Erase-a-base System (Promega, 
Madison, Wisconsin). After ligation, the plasmids were electroporated 
in E. coil DH5~F'IQ and selected with ampicillin (50 i~g/ml). Clones 
were isolated, plasmid DNA was extracted from each clone and 
transfected into COS-7 cells together with an HLA-Cw*1601 cDNA. 
Antigenic Peptides and CTL Assay 
Peptides were synthesized on solid phase using Fmoc for transient 
NH2-terminal protection as described by Atherton et al. (1981) and 
characterized by mass spectrometry. All peptides were >90% pure 
as indicated by analytical high pressure liquid chromatography. Lyoph- 
ilized peptides were dissolved at 20 mg/ml in DMSO, diluted at 2 rag/ 
ml in 10 mM acetic acid, and stored at -80°C. Peptides were tested in 
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a CTL stimulation assay with COS-7 cells transfected by H LA-Cw * 1601 
and incubated with the peptides. They were also tested by chromium 
release assay as previously described (Boon et al., 1980). In this pep- 
tide sensitization assay, target cells were ~lCr-labeled for 1 hr at 37°C 
and washed extensively. Then 1000 target cells were incubated in 
96-well microplates in the presence of various concentrations of pep- 
tide for 30 min at 37°C before CTL 82•82 cells were added. Chromium 
release was measured after 4 hr at 37°C. 
TCR Va and VI} PCR Amplification 
Total RNA from the different CTL clones was prepared by using RNA- 
zol* B (Cinna/Biotecx, Friendswood, Texas) (Chomczynski and Sacchi, 
1987). Single-stranded cDNA synthesis was carried with oligo(dr) and 
Moloney murine leukemia virus-derived reverse transcriptase without 
RNAse H activity (MMLV RT RNAse H, Superscript, GIBCO BRL, 
Rockville, Maryland). PCR was carried out by amplification of TCR~ 
and TCRI~ cDNA with the oligonucleotide primers complementary to 
TCR variable (V(~1-W29, VI~l-W24) and constant (Co{, CI~) region se- 
quences described by Genev~e et al. (1992). Specificity of TCR V(1 
and VI3 PCR amplification was assessed by Southern blotting and 
hybridization with ~2P-labeled C(x or Cl~ oligonucleotides internal to the 
ones used for amplification. 
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